Novartis is cleaning house, cutting its Huntington’s disease program along with several others. The company announced multiple program stops and delays in its full-year 2022 report Wednesday.
If you are not happy with the results below please do another search
50 search results for:
GSK on Wednesday beat fourth-quarter profit and sales forecasts helped by sales of its blockbuster shingles vaccine Shingrix and unveiled an upbeat forecast for 2023.
The firm will seek to acquire and combine best-in-class companies with recognized expertise in global market access, medical affairs, patient services, and data and analytics.
As the 118th Congress kicks into gear, biopharma industry observers speculate that 2023 may be a challenging year.
Novartis on Wednesday predicted that core operating income would grow in a “mid single digit” percentage range in 2023 following stagnation last year, as the Swiss drugmaker prepares to spin off its Sandoz generics business.
Danish drug developer Novo Nordisk on Wednesday presented “strong” sales expectations for 2023 and announced heavy investments into its production capacity, but warned of supply constraints on its best-selling drug.
The U.S. government on May 11 will end the COVID-19 Public Health Emergency (PHE) that allowed millions of Americans to receive vaccines, tests, and treatments at no cost during the pandemic.
The U.S. Food and Drug Administration (FDA) said on Tuesday it will restructure its food program that was slammed last year for responding too slowly to an outbreak of illness among infants who consumed formula from an Abbott Laboratories production plant.
Tuesday, de-extinction company Colossal Biosciences closed a mammoth, $150 million Series B financing round and announced plans to resurrect the iconic Dodo – extinct since the 17th century.
uniQure inked a deal with Apic Bio Tuesday to gain development and commercialization rights for APB-102, a therapeutic intended to treat a rare, genetic form of ALS.